Baidu Inc vs Charles River Laboratories Intl. Inc — how do they compare? Baidu Inc trades at $111 (market cap $36.80B), while Charles River Laboratories Intl. Inc trades at $232.3 (market cap $11.14B). The key difference: Baidu Inc is far larger — about 3.3× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Baidu Inc nearer its low. Which is the better fit depends on your goals.
| BIDU | CRL | |
|---|---|---|
Market Cap | $36.80B | $11.14B |
Sector | Media | Health |
52-Week High | $162.52 | $233.60 |
52-Week Low | $85.86 | $145.57 |
Enterprise Value | $33.45B | $14.00B |
Signals from Pluang's Aura AI — not financial advice
Baidu (BIDU) trades at $113.39, down 3.52% amid bearish technical signals and mixed fundamentals. The stock faces pressure from declining revenue and net income margins, though it maintains strong analyst support with a $161 consensus price target. Recent news highlights AI optimism from Kunlunxin's potential $50 billion Hong Kong IPO, while cash flow trends show significant investing outflows. Technical indicators show bearish moving averages with neutral oscillators, trading near key support at $112.
Baidu presents a high-risk opportunity with Wall Street maintaining bullish ratings despite recent earnings volatility. The AI pivot and potential chip unit IPO offer growth catalysts, but declining profitability and negative cash flows pose substantial risks. Investors should weigh strong balance sheet strength against execution challenges in China's competitive tech landscape.
No Aura AI signal available yet.
Trailing returns across standard periods
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →